BioMarin Pharmaceutical (BMRN): Hedge Funds Back Biotech Leader Amid Record Revenue Growth
Goldman Sachs predicts a drop in S&P 500 returns due to market concentration in top stocks. They suggest the growth rate will decline as it's hard to sustain high levels for long. Despite this, they foresee growth in the remaining index stocks.